Clinical trial
SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With…
NCT00495547 · PETHEMA Foundation, Other · Terminated
Key facts
| NCT number | NCT00495547 |
|---|---|
| Title | SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome |
| Official title | A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk. |
| Acronym | SIMIDIS |
| Lead sponsor | PETHEMA Foundation, Other |
| Collaborators | Roche Pharma AG Industry Celgene Corporation |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Azacitidine, Beta Erythropoietin |
| Enrollment | 16 |
| Start date | Feb 1, 2009 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Jul 3, 2007 |
| Last update posted | Apr 7, 2014 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: